MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook

MIMEDX GROUP, INC.

2025-Q1 EPS reported $0.05 revenue$88,205,000

Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).
Gross margin fell to 81% from 85% on product mix; Surgical products grew 16%, Wound fell 2%.
Cash $106M; net debt $0; 2025 outlook: high single-digit sales growth and >20% Adj. EBITDA margin.
CEO calls LCD delay disappointing; added CELERA product as contingency for affected settings.
SG&A rose to $60M from $55M on higher commissions, salaries, and legal/regulatory costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.